Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akari Therapeutics PlcAKTX · Entity 7692 | Chief Business Officer | October 12, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akari Therapeutics Plc
Report date October 12, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.94 · Expires 2036-10-05 | Direct | 87,000 |
Reported balance
After 2026-10-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-12 · Grant · Acquired 87,000 · Balance 87,000 F1: On October 5, 2026 (the "Grant Date"), the reporting person was granted an option to purchase 87,000 ADSs. This option grant is subject to forfeiture and cancellation if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan is not obtained. The option will vest with respect to 25% on the 12-month anniversary of the Grant Date, with the remainder vesting in equal monthly installments over the next 36 months until fully vested on the 4-year anniversary of the Grant Date, subject to the grantee's continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 5, 2026 (the "Grant Date"), the reporting person was granted an option to purchase 87,000 ADSs. This option grant is subject to forfeiture and cancellation if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan is not obtained. The option will vest with respect to 25% on the 12-month anniversary of the Grant Date, with the remainder vesting in equal monthly installments over the next 36 months until fully vested on the 4-year anniversary of the Grant Date, subject to the grantee's continued service with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 12, 2026 Filed Oct 14, 2026 21:21 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 87,000 | $0.00 Strike: $8.94 | $0.00 |
DisclosureSEC source: 0001493152-26-047058 · ownership.xml · derivative · entry 1 Vat-Ho Vatnak · CIK 0002160022 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,000 Underlying: American Depositary Shares representing Ordinary Shares · 87,000 shares Expires 2036-10-05 F1 · derivative.exercise_date: On October 5, 2026 (the "Grant Date"), the reporting person was granted an option to purchase 87,000 ADSs. This option grant is subject to forfeiture and cancellation if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan is not obtained. The option will vest with respect to 25% on the 12-month anniversary of the Grant Date, with the remainder vesting in equal monthly installments over the next 36 months until fully vested on the 4-year anniversary of the Grant Date, subject to the grantee's continued service with the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.